10:14 AM
 | 
Dec 07, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS). The small molecule quinuclidinone is designed to promote correct folding and therefore restore wild-type conformation and function of p53, a tumor suppressor gene which is mutated in more than 50% of all human cancers.

Formed in 2003 and backed by Karolinska Development AB (SSE:KDEV) for more than a decade, Aprea jump-started its clinical development with a €46 million ($50.4 million)...

Read the full 462 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >